ALDX
Income statement / Annual
Last year (2023), Aldeyra Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Aldeyra Therapeutics, Inc.'s net income was -$37.54 M.
See Aldeyra Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$262,780.00 |
$258,707.00 |
$264,180.00 |
$56,221.00 |
$96,305.00 |
$71,003.00 |
$37,849.00 |
$35,792.00 |
$18,778.00 |
$0.00 |
| Gross Profit |
-$262,780.00 |
-$258,707.00 |
-$264,180.00 |
-$56,221.00 |
-$96,305.00 |
-$71,003.00 |
-$37,849.00 |
-$35,792.00 |
-$18,778.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$29.46 M
|
$47.31 M
|
$44.94 M
|
$24.68 M
|
$44.35 M
|
$29.82 M
|
$16.30 M
|
$13.18 M
|
$7.57 M
|
$3.71 M
|
| General & Administrative
Expenses |
$13.34 M
|
$15.37 M
|
$11.28 M
|
$9.99 M
|
$12.15 M
|
$9.88 M
|
$6.19 M
|
$5.52 M
|
$4.41 M
|
$3.56 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.34 M
|
$15.37 M
|
$11.28 M
|
$9.99 M
|
$12.15 M
|
$9.88 M
|
$6.19 M
|
$5.52 M
|
$4.41 M
|
$3.56 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2.33 M |
| Operating Expenses |
$42.79 M |
$62.68 M |
$56.22 M |
$34.67 M |
$56.51 M |
$39.70 M |
$22.49 M |
$18.70 M |
$11.99 M |
$7.27 M |
| Cost And Expenses |
$42.79 M |
$62.68 M |
$56.22 M |
$34.67 M |
$56.51 M |
$39.70 M |
$22.49 M |
$18.70 M |
$11.99 M |
$7.27 M |
| Interest Income |
$7.32 M |
$2.35 M |
$185,363.00 |
$292,224.00 |
$1.54 M |
$952,698.00 |
$261,252.00 |
$102,037.00 |
$11,126.00 |
$3.00 |
| Interest Expense |
$2.07 M |
$1.69 M |
$1.74 M |
$1.90 M |
$603,846.00 |
$146,792.00 |
$113,454.00 |
$105,509.00 |
$112,306.00 |
$244,174.00 |
| Depreciation &
Amortization |
$262,780.00
|
$258,707.00
|
$264,180.00
|
$56,221.00
|
$96,305.00
|
$71,003.00
|
$37,849.00
|
$35,792.00
|
$18,778.00
|
$1,069.00
|
| EBITDA |
-$35.21 M
|
-$60.07 M
|
-$55.77 M
|
-$36.07 M
|
-$61.44 M
|
-$38.68 M
|
-$22.19 M
|
-$18.56 M
|
-$11.96 M
|
-$4.94 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$5.25 M
|
$655,351.00
|
-$1.56 M
|
-$3.37 M
|
-$5.63 M
|
$805,906.00
|
$147,799.00
|
-$3,472.00
|
-$101,180.00
|
$2.08 M
|
| Income Before Tax |
-$37.54 M |
-$62.02 M |
-$57.78 M |
-$38.03 M |
-$62.14 M |
-$38.89 M |
-$22.34 M |
-$18.70 M |
-$12.09 M |
-$5.19 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$655,351.00 |
$1.48 M |
-$479,265.00 |
-$1.31 M |
$952,698.00 |
$223,403.00 |
$66,245.00 |
-$7,652.00 |
$243,105.00 |
| Net Income |
-$37.54 M |
-$61.37 M |
-$59.25 M |
-$37.55 M |
-$60.83 M |
-$38.89 M |
-$22.34 M |
-$18.70 M |
-$12.09 M |
-$5.19 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.64 |
-1.05 |
-1.1 |
-1.11 |
-2.24 |
-1.79 |
-1.4 |
-1.65 |
-1.4 |
-1.36 |
| EPS Diluted |
-0.64 |
-1.05 |
-1.1 |
-1.11 |
-2.24 |
-1.79 |
-1.4 |
-1.65 |
-1.4 |
-1.35 |
| Weighted Average Shares
Out |
$58.94 M
|
$58.41 M
|
$54.04 M
|
$33.97 M
|
$27.11 M
|
$21.69 M
|
$15.92 M
|
$11.35 M
|
$8.63 M
|
$3.82 M
|
| Weighted Average Shares
Out Diluted |
$58.94 M
|
$58.41 M
|
$54.04 M
|
$33.97 M
|
$27.11 M
|
$21.69 M
|
$15.92 M
|
$11.35 M
|
$8.63 M
|
$3.85 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
